The Filing Desk

Starling Oncology vs GeneDx

Starling Oncology STLN · GeneDx WGS · Health Care Services

Starling Oncology reported revenue of $503 million in fiscal 2025, 1.2 times GeneDx's $428 million in fiscal 2025. Starling Oncology's revenue grew 27.8% in its latest year, and GeneDx's grew 40.0%. Starling Oncology had an operating margin of -7.2%, against -3.1% at GeneDx. Free cash flow was −$28 million at Starling Oncology and $14 million at GeneDx.

Side by side

Starling OncologyGeneDx
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$503M$428M
Revenue growth27.8%40.0%
Revenue growth a year, last 5 years21.8%19.0%
Gross margin—69.7%
Operating margin−7.2%−3.1%
Net margin−12.1%−4.9%
Free cash flow−$28M$14M
Free cash flow margin−5.5%3.3%
Return on capital−75.7%−5.3%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.1%6.5%
Last close$3.50$52.37
P/E at the last close——
Insider trades, last 12 months—bought $106.6 million, sold $21.5 million
Piotroski F-score3 of 86 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Starling OncologyGeneDx
Operating margin
Percent of revenue
Starling OncologyGeneDx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Starling OncologyGeneDx

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Starling Oncology and GeneDx pages.